On February 8, 2018 Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ) reported that it will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN data for the investigational compound apalutamide in non-metastatic castration-resistant prostate cancer (Press release, Johnson & Johnson, FEB 8, 2018, View Source [SID1234523840]). The webcast is intended for investors and other interested parties, and will be available beginning at 5:00p.m EST on Thursday, February 8, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded webcast will feature Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, who will recap pivotal Phase 3 apalutamide data, which were featured at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary (ASCO GU) 2018 Cancers Symposium. Dr. Lebowitz will also highlight the company’s prostate cancer strategy and portfolio.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations." The webcast duration is approximately 12 minutes and will be available through the end of April.

On February 8, 2018 Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported its participation in the Leerink Partners 7th Annual Global Healthcare Conference (Press release, Kura Oncology, FEB 8, 2018, View Source [SID1234524047]). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Thursday, February 15, 2018 at 11:30 a.m. EST (8:30 a.m. PST). The conference will be held from February 14-15 in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available in the Investors section of Kura Oncology’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

On February 8, 2018 Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immune-based products, reported that President and CEO Lewis H. Bender would be speaking on a CEO Panel titled: Raising Capital in the Current Market during the Immuno-Oncology 360° conference at the Roosevelt Hotel in New York City, NY February 7-9, 2018 (Press release, Intensity Therapeutics, FEB 8, 2018, View Source [SID1234524352]). IO360 aims to provide a comprehensive program encompassing all facets of IO including discovery, business development, finance, and emerging trends. Mr. Bender’s panel discussion is on February 9, 2018 at 1:45PM.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Mr. Bender will make a corporate presentation and provide an update on the company’s clinical trial of lead drug, INT230-6, on Monday February 12 at 11:15AM in the Brecht room during the 20th annual BIO CEO & Investor Conference being held at the New York Marriott Marquis hotel in New York City, NY February 12-13.

About INT230-6

INT230-6 is a novel, anti-cancer drug for direct intratumoral injection. The product contains potent anti-cancer agents that disperse throughout tumors and diffuse into cancer cells. In preclinical studies INT230-6 eradicated tumors by a combination of direct tumor kill coupled with recruitment of dendritic cells to the tumor micro-environment that stimulated anti-cancer T-cell activation. INT230-6 provides complete responder animals with long-term, durable protection from multiple re-inoculations of the initial cancer and resistance to other cancers. INT230-6 is being evaluated in clinical study, IT-01, www.clinicaltrials.gov (NCT#03058289).

On February 8, 2018 AskAt Inc. (AskAt), headquartered in Nagoya, Japan, reported a license agreement with NewBay Medical Technology Co., Ltd. (NewBay), headquartered in Hangzhouwan New Zone, Ningbo, Zhejiang Province, People’s Republic of China (China), granting NewBay exclusive rights to develop, manufacture and commercialize AskAt’s EP4 Antagonist [AAT-008] in China in the area of Immuno-Oncology (Press release, AskAt, FEB 8, 2018, View Source [SID1234535052]). Under the terms of the signed agreement, AskAt will receive upfront payments from NewBay and is eligible to receive Development and Commercial Milestone payments and Royalties on sales of products in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About AAT-008

AAT-008 is a novel prostaglandin EP4 antagonist that has exhibited potent anti-tumor activity in animal models of lung, breast, colon, stomach, prostate, and liver cancers, and synergistic activity in combination with anti-PD-1 anti-body.

On February 8, 2018 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, reported that Matthew R. Patterson, President and Chief Executive Officer, will present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY (Press release, Audentes Therapeutics, FEB 8, 2018, View Source;p=RssLanding&cat=news&id=2331287 [SID1234523819]). The presentation is scheduled for Thursday, February 15, 2018, at 10:30 am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. A replay of the live webcast will be available on the Audentes website for approximately 30 days following the conference.